Kalaris Therapeutics, Inc.
KLRS · XNASCIK 1754068fmd_1VE18HN42S6FJJ79CCZ1J8KC88Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 0 | – | – | – | – | – | – |
| Research and development | 16 | 50 | 121 | 119 | 133 | 45 | 31 |
| Total operating expenses | 27 | 71 | 170 | 171 | 200 | 52 | 46 |
| Operating income | (27) | (71) | (170) | (171) | (200) | (52) | (46) |
| Interest expense | – | – | – | – | – | 3 | 1 |
| Interest and investment income | 2 | 1 | 1 | 2 | 6 | 5 | – |
| Other non-operating income (expense) | 1 | 0 | (2) | 0 | 4 | (17) | 3 |
| Income before taxes | (24) | (70) | (171) | (169) | (191) | (69) | (43) |
| Income tax expense | – | – | 1 | (0) | (0) | 0 | 0 |
| Net income from continuing operations | – | – | (172) | (169) | (190) | (69) | (43) |
| Net income | (24) | (70) | (172) | (169) | (190) | (69) | (43) |
| Net income to common shareholders | (24) | (70) | (172) | (169) | (190) | (59) | – |